Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aberrant retinal structure and vasculature in mouse models of dominant retinopathies caused by CRX homeodomain mutations.

Scientific reports·2026
Same author

Clinical Outcomes and Predictors of Retinal Breaks in Patients With Vitreous Hemorrhage Secondary to a Posterior Vitreous Detachment.

Journal of vitreoretinal diseases·2026
Same author

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same author

RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

Investigative ophthalmology & visual science·2026
Same author

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Expert opinion on biological therapy·2026
Same author

Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate.

Cancer discovery·2026

Related Experiment Video

Updated: Jun 16, 2026

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Targeting immune privilege to prevent pathogenic neovascularization.

Jayeeta Roychoudhury1, John M Herndon, Jiyi Yin

  • 1Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.

Investigative Ophthalmology & Visual Science
|February 19, 2010
PubMed
Summary
This summary is machine-generated.

Modulating immune privilege by increasing FasL expression can prevent blinding neovascular eye diseases. This study shows targeting FasL is a promising therapeutic strategy for conditions like choroidal neovascularization (CNV).

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Area of Science:

  • Ophthalmology
  • Immunology
  • Molecular Biology

Background:

  • The immune system plays a key role in blinding eye disorders.
  • The eye's immune privilege is partly maintained by Fas Ligand (FasL) interactions, which regulate inflammation and neovascularization.
  • Modulating immune privilege is explored as a therapeutic strategy for pathogenic angiogenesis in the eye.

Purpose of the Study:

  • To investigate whether modulating immune privilege via FasL can be an effective therapeutic approach for pathogenic angiogenesis in the eye.
  • To test the efficacy of targeting FasL in preventing choroidal neovascularization (CNV).

Main Methods:

  • Laser-induced choroidal neovascularization (CNV) in C57BL/6 mice and FasL-defective B6-gld mice.
  • Treatment with cytotoxic FasL injection or oral doxycycline to modulate FasL expression.
  • Evaluation of CNV, FasL expression, macrophage influx, and soluble FasL (sFasL) levels.

Main Results:

  • Cytotoxic FasL injection prevented neovascularization in the CNV mouse model.
  • Oral doxycycline increased functional FasL in the eye, significantly inhibiting neovascularization.
  • Doxycycline enhanced FasL on RPE cells and reduced circulating and tissue sFasL.
  • Treatment was ineffective in B6-gld mice, confirming FasL mediation.

Conclusions:

  • Targeting immune privilege by increasing FasL expression is a potential therapeutic strategy for neovascular eye diseases.
  • Cytotoxic molecules or agents that increase FasL expression may offer a viable treatment approach for conditions like CNV.